AI-designed drugs that target specific cannabinoid signals
AI-Powered Biased Ligand Design
Researchers are using artificial intelligence to create new cannabinoid-targeting molecules that aim to trigger helpful cell signals while reducing side effects for people who need safer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11291824 on NIH RePORTER |
What this research studies
This project builds AI tools to design 'biased' molecules that activate only desired signaling pathways at cannabinoid receptors CB1 and CB2. The team will train interaction-profile scoring functions to recognize ligand–receptor contact patterns tied to particular cellular responses and use Drug-GAN models to generate novel chemical structures. Top AI-generated candidates will be prioritized for laboratory testing and refinement to find molecules with the intended signaling bias. The goal is to expand the pool of drug-like compounds for targets that have many potent binders but few or no approved medicines.
Who could benefit from this research
Good fit: People who might benefit include patients with conditions treated by cannabinoid-receptor drugs, such as chronic pain, spasticity, chemotherapy-induced nausea, or certain inflammatory disorders.
Not a fit: This is early-stage, preclinical drug-discovery work, so individuals seeking immediate treatment should not expect direct personal benefit.
Why it matters
Potential benefit: If successful, this work could lead to cannabinoid-based medicines that provide benefits with fewer unwanted side effects.
How similar studies have performed: AI and generative models have produced promising new drug candidates in other programs, but using them specifically to design signaling-biased molecules is a newer and less-proven approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Wang, Junmei — University of Pittsburgh at Pittsburgh
- Study coordinator: Wang, Junmei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.